Company intelligence / Profile preview

Vernalis

Cambridge, England, United Kingdomvernalis.com ↗

Ownership: Private
Employees: ~75
Development stage: Preclinical

Overview

Vernalis has a long track record in fragment-based and structure-guided drug discovery. It provides integrated services from protein production through hit identification to lead optimization and preclinical candidate selection. The company’s technologies have enabled the progression of multiple partnered programs against historically challenging or “undruggable” targets. Its legacy includes marketed products such as frovatriptan for migraine but currently focuses on collaborative research rather than proprietary clinical development.

Therapeutic areas: OncologyImmunologyNeurology
Modalities: Small moleculeMonoclonal antibodyPeptidesDNA Encoded Library technology
Industry: Drug Discovery Services

Partnerships

ServierPierre FabreGenentech/RocheLundbeckC4X Discovery

Beyond the preview

Go deeper on Vernalis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vernalis.

Explore the full profile